Transcription of WHO R&D Blueprint novel Coronavirus
{{id}} {{{paragraph}}}
Example: barber
WHO R&D Blueprint novel Coronavirus
WHO R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial Synopsis World Health Organization 2020. All rights reserved. This is a draft. The content of this document is not final, and the text may be subject to revisions before publication. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization. The mention of specific companies or of certain manufacturers products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned.
post randomization. A special WHO committee arrived at the ordinal scale (given in the table below and the Appendix) that measures illness severity over time. The primary outcome could be a measure of patients' clinical status at a particular time point after enrolment, depending upon frequency of outcome assessment (e.g., 14, 28, or 60 days).
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: